Core Points - NKGen Biotech, a clinical-stage biotechnology company, is focused on developing innovative NK cell therapeutics and will present at the XXVII World Congress of Neurology in Seoul, South Korea from October 12-15, 2025 [1][2] - The presentation will highlight the scientific rationale and clinical findings for troculeucel, an investigational autologous NK cell therapy aimed at treating Alzheimer's disease, demonstrating the company's commitment to advancing neurological care [2][3] Company Overview - NKGen Biotech is headquartered in Santa Ana, California, and specializes in the development and commercialization of autologous and allogeneic NK cell therapeutics [5] - Troculeucel, the company's novel cell-based immunotherapeutic drug candidate, is designed for treating neurodegenerative disorders and various cancers, with its International Nonproprietary Name (INN) assigned as SNK01 by the WHO [4] Presentation Details - The presentation titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer's Disease" will be delivered by Paul Y. Song, M.D. on October 15, 2025, at 11:50 AM KST [3] - The session will focus on ataxia, cerebellar disorders, and dementia, and a copy of the presentation will be available on the company's website post-event [3]

Core Viewpoint - NKGen Biotech, Inc. has successfully raised $2 million from a Japanese strategic investor to support the development of its NK cell therapy, troculeucel, and to regain compliance with financial reporting obligations [2][3][4] Funding and Financial Compliance - The new funding consists of common stock priced at $0.25 per share and warrants, aimed at addressing the company's reporting obligations and listing standards [3] - The company plans to temporarily move its share trading to the OTC Expert Market, with the potential to uplist to OTCQB once SEC filings are current, and aims to return to Nasdaq or NYSE American thereafter [4] Strategic Developments - The investment comes at a critical time following the bankruptcy of NKGen's former parent company, NKMax Co., Ltd., which had disrupted capital raising efforts [4] - The company has secured a majority stake in NKMax out of bankruptcy, which is expected to close soon, allowing consolidation of key intellectual property rights across Asia [4] Product Development - Troculeucel is being developed for neurodegenerative disorders and various cancers, with its International Nonproprietary Name (INN) approved by the WHO, marking a significant milestone for NKGen [6] Future Plans - The company is committed to regaining compliance with financial filings and aims to uplist to Nasdaq or NYSE American as soon as it meets the necessary requirements [4]